Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Amortizatization of Intangibles (2019 - 2025)

Historic Amortizatization of Intangibles for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Q3 2025 value amounting to $3.6 million.

  • Crinetics Pharmaceuticals' Amortizatization of Intangibles rose 250.5% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 1743.31%. This contributed to the annual value of $14.9 million for FY2024, which is 13809.6% up from last year.
  • Crinetics Pharmaceuticals' Amortizatization of Intangibles amounted to $3.6 million in Q3 2025, which was up 250.5% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $4.7 million in Q2 2025 and a low of -$322000.0 during Q1 2022
  • In the last 5 years, Crinetics Pharmaceuticals' Amortizatization of Intangibles had a median value of $911000.0 in 2023 and averaged $1.8 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Amortizatization of Intangibles crashed by 28795.18% in 2022 and then skyrocketed by 92108.26% in 2023.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Amortizatization of Intangibles stood at -$186000.0 in 2021, then surged by 288.71% to $351000.0 in 2022, then skyrocketed by 921.08% to $3.6 million in 2023, then grew by 16.16% to $4.2 million in 2024, then fell by 13.5% to $3.6 million in 2025.
  • Its Amortizatization of Intangibles was $3.6 million in Q3 2025, compared to $4.7 million in Q2 2025 and $4.4 million in Q1 2025.